具体内容如下： 一、公司 2025 年上半年经营情况介绍 在医药行业筑底回暖的背景下，公司结合医药行业变化趋势中呈现的积极信号，持续推动战略落地。报告 期内，公司实现营业总收入 31.88 亿元，同比增长 18.20%，其中第二季度实现收入 16.47 亿元，环比一季 度增长 6.87%。随着降本增效措施效果显现，以及新兴业务交付规模提升和产能利用率爬坡，实现归属于 上市公司股东的净利润 6.17 亿元，同比增长23.71%，净利润增长较营业收入增长高 5.51 个百分点。 公司 上半年归母净利率 19.4%，同比增长近 1个百分点，持续靠近大订单之前的历史常规水平。 各板块业务发展介绍、经营展望、资本开支等请见《2025年 8月 26 日凯莱英特定对象调研演示资料》。 问：投资者答交流 答：二、投资者问交流 问：公司上半年新兴业务整体在手订单增长较快，请拆分业务板块在手订单分别表现如何？ 随着公司新 兴业务规模效应的升，上半年毛利率大幅升，请稳态后新兴业务利润率如何展望？ 答：今年上半年新兴业务在手订单增长主要的驱动板块为化学大分子和生物大分子。其中，偶联药物的新 签订单增幅最大，同比超过 100%；其次为 ...

Core Viewpoint - Novartis plans to acquire Avidity Biosciences, a leader in the AOC field with a market value of nearly $6 billion, to strengthen its pipeline in the rare disease treatment sector [3]. Group 1: Market Dynamics - The small nucleic acid drugs, including siRNA, ASO, and miRNA, are designed to regulate gene expression for disease treatment, offering breakthrough therapies for genetic, rare, and chronic diseases [4]. - Novartis faces a "patent cliff" with several blockbuster drugs, including Entresto, set to lose patent protection between 2025 and 2030, necessitating the acquisition of new pipeline assets to ensure future growth [5]. - Major pharmaceutical companies, including Sanofi, Pfizer, and Eli Lilly, have been actively acquiring and partnering in the small nucleic acid drug space to capture the potential market [6]. Group 2: AOC Development and Commercialization - AOC (Antibody-Oligonucleotide Conjugates) represents an innovative delivery method for small nucleic acid drugs, combining the targeting ability of monoclonal antibodies with the gene regulation capabilities of oligonucleotides [10]. - Avidity Biosciences is a leading player in the AOC field, with three pipelines in Phase III clinical trials, including a drug for Duchenne Muscular Dystrophy (DMD) that has shown promising results [12]. - The commercialization of AOC drugs is expected to accelerate, with several biotech companies entering late-stage clinical trials, aiming for market entry around 2026-2027 [11]. Group 3: Investment and Policy Support - The Chinese government continues to support the development of RNA and small nucleic acid drugs through funding initiatives aimed at overcoming core bottlenecks in drug creation [14]. - Recent financing activities in the small nucleic acid drug sector indicate growing interest and investment, with several companies securing significant funding [17]. - Novartis's acquisition of Avidity, if completed, would mark a significant milestone in the global AOC drug market, highlighting the increasing focus on innovative therapies [15].

诺华重注小核酸肝外递送 2025-08-20 诺华重注小核酸肝外递送 原创 来觅研究院 RimeData 来觅数据 撰稿 张梓英 2025-08-20 导读： 8 月 7 日消息，诺华拟收购目前市值近 60 亿美元的 AOC 领域领军者 Avidity Biosciences （NASDAQ：RNA），旨在通过扩充管线强化罕见病治疗领域的核心布局。据介绍，Avidity Biosciences 是一家致力于提供一类名为抗体寡核苷酸偶联药物（AOC）的新型 RNA 疗法的生物制药公司，目前旗下 共有三条处于临床阶段的 AOC 管线。 小核酸药物（寡核苷酸药物）是一类通过调控基因表达实现疾病治疗的生物大分子药，包括 siRNA、ASO、 miRNA 等，其作用机制主要基于碱基互补配对原则：siRNA 通过 RNA 干扰（RNAi）途径降解靶 mRNA， ASO 通过空间位阻或 RNase H 介导的切割抑制蛋白翻译，miRNA 则通过调控多基因网络影响细胞功 能，这类药物的核心优势在于能靶向传统"不可成药"的致病基因，在基因层面直接调控疾病相关蛋白的 表达，为遗传病、罕见病和慢性病提供了突破性治疗手段。这类药物疗 ...

Core Viewpoint - The recent financial report of Fuyuan Pharmaceutical (601089) indicates a decline in net profit and revenue, highlighting challenges in the company's performance for the first half of 2025 compared to the previous year [1] Financial Performance Summary - The total operating revenue for the first half of 2025 was 1.634 billion yuan, a decrease of 1.3% year-on-year [1] - The net profit attributable to shareholders was 268 million yuan, down 7.83% year-on-year [1] - The gross profit margin was 66.49%, a slight decrease of 0.3% compared to the previous year [1] - The net profit margin fell to 16.43%, down 6.99% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 613 million yuan, accounting for 37.54% of revenue, an increase of 2.73% year-on-year [1] - Earnings per share decreased to 0.56 yuan, down 8.2% year-on-year [1] - Operating cash flow per share was 0.45 yuan, a significant decrease of 37.03% year-on-year [1] Significant Financial Changes - Cash and cash equivalents increased by 21.81% due to the redemption of maturing financial products [3] - Trade receivables rose by 4.65%, while short-term borrowings decreased by 100% as a subsidiary repaid bank loans [3] - The company reported a 4409.28% increase in investment income due to higher returns from bank financial products [3] - The net cash flow from operating activities decreased by 37.03% due to reduced cash collections and increased expenses [3] Business Model and Strategy - The company relies heavily on research and marketing for its performance, with a focus on innovative drug development, particularly in nucleic acid drugs targeting cancer and chronic kidney disease [6][9] - The company has a comprehensive sales network and plans to optimize its sales management system to enhance operational efficiency and market responsiveness [11] Future Outlook - The company aims to maintain its R&D investment, with a projected increase of 18.13% in R&D expenses for 2024 [9] - The company has set ambitious operational goals, although achieving these will depend on various external factors [13]

Core Insights - The recent bio-manufacturing forum in Suzhou focuses on cutting-edge technologies and aims to facilitate technology transfer and industrial collaboration in the bio-manufacturing sector [1] - Bio-manufacturing is seen as a key driver of the "Fourth Industrial Revolution" and is crucial for developing new productive forces across various fields such as pharmaceuticals, agriculture, and food [1] - Suzhou Industrial Park is actively positioning itself in the bio-manufacturing sector, leveraging its strong industrial foundation and complete supply chain to seize development opportunities [1] Industry Development Plans - In March, Suzhou Industrial Park announced a three-year action plan to accelerate the development of the bio-manufacturing industry, focusing on synthetic biology, biopharmaceuticals, food, bio-based materials, and bio-manufacturing equipment [1][2] - The plan aims to enhance innovation capabilities, achieve scale effects, and improve the industrial ecosystem by 2027, with specific support in R&D, platform construction, innovation incubation, and collaborative development [2] Company Highlights - Suzhou has over 40 companies related to synthetic biology technology, accounting for nearly 60% of the total in the city [2] - Jinweizhi Biotechnology Co., Ltd. specializes in genomic research and technology applications, collaborating with 80% of the top 20 global pharmaceutical companies and serving multiple regions including China, North America, Europe, Southeast Asia, and Australia [2] - Jima Gene Co., Ltd. is a leading provider of RNA drug technology services in China, focusing on small nucleic acid technology and has established a pilot platform for nucleic acid drug research in collaboration with the National Biopharmaceutical Technology Innovation Center [3] Collaborative Models - The collaboration between national research centers and leading enterprises in Suzhou accelerates the overall industrial process of bio-manufacturing through a "national team + enterprise group" model [3] - The park plans to establish common technology platforms and resource libraries, including a microbial strain preservation library, to support high-throughput, intelligent, and automated pilot platforms [3]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Viewpoints - The report highlights that the demand for hepatitis B cure remains a blue ocean, with CpAMs and small nucleic acid drugs expected to lead the way in achieving functional cures. The large base of hepatitis B infections in China and the limitations of existing therapies create a pressing need for effective treatments [4][15] - The implementation of the "Childcare Subsidy System" is expected to enhance the willingness of families to have children, positively impacting related sectors such as pediatric medicine, medical equipment, and maternal health services [6][21][23] - The pharmaceutical sector saw an overall increase of 2.95% this week, outperforming the CSI 300 index by 4.70 percentage points, with the chemical preparation sector showing the highest growth at 5.48% [25][26] Summary by Sections 1. Hepatitis B Treatment Opportunities - The report emphasizes the significant unmet need for hepatitis B cures in China, with approximately 56 million chronic carriers and a high percentage at risk of severe liver disease [15] - Current approved treatments are limited, with nucleos(t)ide analogs (NAs) and pegylated interferon-α showing inadequate rates of functional cure [15][16] - New drug classes, including CpAMs and small nucleic acids, are in advanced clinical stages, with companies like GSK and AHB-137 leading the way [17][18] 2. Childcare Subsidy System - The newly announced childcare subsidy will provide annual financial support of 3,600 yuan per child under three years old, starting from January 1, 2025 [21][22] - This initiative is expected to boost sectors related to child healthcare and maternal services, enhancing market opportunities for companies in these fields [23][24] 3. Weekly Performance of Pharmaceutical Sector - The pharmaceutical sector's performance this week was marked by a 2.95% increase, with the chemical preparation sector leading at 5.48% [25][26] - The report notes a significant divergence in performance among sub-sectors, with medical devices experiencing a decline of 1.43% [26][32] 4. Beneficiary Stocks - The report identifies several beneficiary stocks across various segments, including innovative drugs (e.g., Innovent Biologics, BeiGene), traditional Chinese medicine (e.g., Jiuzhitang), and medical devices (e.g., Mindray Medical) [8][9][33][40] 5. Market Outlook - The report suggests a positive outlook for innovative drugs driven by overseas expansion and supportive policy developments, with a focus on companies with strong clinical data and market potential [31] - The medical device sector is expected to benefit from upcoming procurement policies and a recovery in demand, particularly for high-end equipment [32][33]

Group 1: Natural Gas Development in the Middle East - The acceleration of natural gas development in the Middle East is driven by the energy transition and increasing power generation demand, creating a strategic window for development [3][5] - Two leading equipment companies have secured significant orders in the Middle East, with one company obtaining a $1.5 billion order, accounting for 10% of the market share, and another company expected to double its orders over three years [2][3] - The expansion of the entire natural gas extraction, processing, liquefaction, and transportation chain is anticipated to significantly boost engineering construction and high-end equipment demand in the region [3] Group 2: Small Nucleic Acid Drugs in the Pharmaceutical Industry - Small nucleic acid drugs are emerging as the third major category of pharmaceuticals, with Chinese pharmaceutical companies securing over $6 billion in business development (BD) deals [7][8] - The market for small nucleic acid drugs is expected to grow, particularly in chronic disease treatment, with a focus on hepatitis B and cardiovascular diseases [7][8] - The increasing frequency of large BD deals highlights the potential of early-stage chronic disease pipelines in the pharmaceutical sector [8]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][44] Core Views - The pharmaceutical sector is expected to experience a rebound in 2025, driven by innovation in drugs and medical devices, with a focus on low-valuation assets related to aging and overseas expansion [44] - The small nucleic acid drug market is entering a rapid development phase, with significant potential reflected in the performance of leading companies like Alnylam [4][8] - The report emphasizes the importance of innovation in the pharmaceutical industry, highlighting the successful transition of traditional pharmaceutical companies to innovative drug development [44] Summary by Sections Market Performance - From July 21 to July 25, the pharmaceutical index rose by 1.90%, outperforming the CSI 300 index by 0.21% [5][28] - Notable gainers included Haitai Biological (+46.93%), Zhendong Pharmaceutical (+42.89%), and Saily Medical (+31.73%) [5][28] Small Nucleic Acid Development - Small nucleic acid drugs, particularly siRNA and ASO, are gaining traction, with Alnylam leading the market [8][13] - Alnylam's market capitalization reached $42.8 billion as of July 24, 2025, reflecting its successful commercialization of siRNA therapies [13][20] Investment Recommendations - Key stocks to watch include innovative drug companies such as Heng Rui Pharmaceutical, Keren Pharmaceutical, and Xinlitai, as well as companies involved in overseas expansion like Mindray Medical and Yuyue Medical [4][44][45] - The report suggests focusing on sectors with low valuations, including medical devices and high-barrier industries like blood products and narcotics [44][45] Industry Trends - The report identifies several positive factors for the pharmaceutical industry, including the scaling of domestic innovation, increasing overseas capabilities, and the growing demand from an aging population [44] - The report also notes the ongoing development of a multi-layered payment system, which is expected to support industry growth [44] Valuation Insights - As of July 25, 2025, the overall PE valuation for the pharmaceutical sector is 37.98X, indicating that valuations are still relatively low compared to historical levels [37][44]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6]. Core Insights - Small nucleic acid drugs are expected to become the third major class of drugs after small molecules and antibodies, with unique advantages such as broad targets, strong specificity, high development efficiency, and long dosing intervals [9][38]. - The commercialization of rare diseases is maturing, and the long-term advantages for chronic diseases are becoming evident, with significant sales growth for products like Spinraza and Leqivo [9][60]. - There is a notable increase in business development (BD) activities, highlighting the potential of early-stage chronic disease pipelines [9]. Summary by Sections 1. Small Nucleic Acids: Potential as a New Drug Class - Small nucleic acid drugs, including ASO, siRNA, and Aptamer, interact with mRNA to regulate gene expression, offering a new technological pathway for drug development [13]. - The global market for small nucleic acid drugs has grown from $1.04 billion in 2017 to $5.09 billion in 2024, with a CAGR of 25.5% [60]. 2. Milestones in Overseas and Domestic Markets - In the overseas market, significant developments are expected in the TTR field and cardiovascular diseases, with drugs like Vutrisiran and Pelacarsen showing promise [9]. - In China, new therapies for chronic hepatitis B and competitive advancements in cardiovascular drugs are emerging, with several companies making progress in their pipelines [9][60]. 3. Investment Recommendations and Targets - The report suggests focusing on high-quality domestic companies involved in the development of small nucleic acid drugs targeting chronic hepatitis B and cardiovascular diseases, such as HengRui Medicine, China National Pharmaceutical Group, and others [9].

Company Insights - Tesla reported disappointing Q2 earnings with revenue of $22.5 billion, a 12% year-over-year decline, and adjusted net profit of $1.393 billion, down 23% year-over-year. The company also warned of a challenging outlook for the upcoming quarters, anticipating tariff costs of approximately $300 million [2] - Container orders for industrial robots have surged, with some companies reporting orders extending to November. This indicates a rapid acceleration in the robotics industry, driven by ongoing developments in Tesla's robotics initiatives and the completion of IPO preparations by related firms [13] Industry Insights - The General Administration of Customs of China released interim measures for tax management of duty-free goods processed in Hainan Free Trade Port, allowing goods with over 30% value added from imported materials to enter mainland China without import duties [3] - The Ministry of Agriculture and Rural Affairs emphasized the need for high-quality development in the pig industry, focusing on market guidance and policy support to stabilize the market and promote industry transformation [4] - The Shanghai Stock Exchange is focusing on nurturing quality technology enterprises, particularly in the field of artificial intelligence, to enhance service across the entire lifecycle and business chain of these companies [5] - The biotechnology company Abivax's small nucleic acid drug has shown positive results, leading to a stock price surge of over 596%. The year 2025 is highlighted as significant for small nucleic acid drug investments due to advancements in delivery platforms and expanded indications [11]